Bad neighbours: hypoxia and genomic instability in prostate cancer
AffiliationTranslational Oncogenomics, CRUK Manchester Institute and CRUK Manchester Centre, Manchester,
MetadataShow full item record
AbstractProstate cancer (PCa) is a clinically heterogeneous disease and has poor patient outcome when tumours progress to castration-resistant and metastatic states. Understanding the mechanistic basis for transition to late stage aggressive disease is vital for both assigning patient risk status in the localised setting and also identifying novel treatment strategies to prevent progression. Subregions of intratumoral hypoxia are found in all solid tumours and are associated with many biologic drivers of tumour progression. Crucially, more recent findings show the co-presence of hypoxia and genomic instability can confer a uniquely adverse prognosis in localised PCa patients. In-depth informatic and functional studies suggests a role for hypoxia in co-operating with oncogenic drivers (e.g. loss of PTEN) and suppressing DNA repair capacity to alter clonal evolution due to an aggressive mutator phenotype. More specifically, hypoxic suppression of homologous recombination represents a 'contextual lethal' vulnerability in hypoxic prostate tumours which could extend the application of existing DNA repair targeting agents such as poly-ADP ribose polymerase inhibitors. Further investigation is now required to assess this relationship on the background of existing genomic alterations relevant to PCa, and also characterise the role of hypoxia in driving early metastatic spread. On this basis, PCa patients with hypoxic tumours can be better stratified into risk categories and treated with appropriate therapies to prevent progression.
CitationAshton J, Bristow R. Bad neighbours: hypoxia and genomic instability in prostate cancer. The British journal of radiology. 2020:20200087.
JournalBritish Journal of Radiology
- Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer.
- Authors: Taiakina D, Dal Pra A, Bristow RG
- Issue date: 2014
- Genomic Markers in Prostate Cancer Decision Making.
- Authors: Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP
- Issue date: 2018 Apr
- CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
- Authors: Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H
- Issue date: 2017 Jul 1
- Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.
- Authors: Wu M, Wang X, McGregor N, Pienta KJ, Zhang J
- Issue date: 2014 Jun
- Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
- Authors: Castro E, Mateo J, Olmos D, de Bono JS
- Issue date: 2016 Sep/Oct